BMGLHealthcare · Medical Care FacilitiesBMGL Stock Forecast: Basel Medical Group Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 4 Nov 2026 — in the weakest quartile.
BMGL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Basel Medical Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (90): Sales and profits are climbing, and climbing faster than before.
Volatility (12): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BMGL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BMGL, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
BMGL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BMGL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Basel Medical Group Ltd. (BMGL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 115.0×
- Price / sales
- 3.3×
- Price / book
- 2.1×
- EV / EBITDA
- −38.1×
Cheaper than 6% of US stocks
Cheaper than 36% of US stocks
Cheaper than 41% of US stocks
Cheaper than 93% of US stocks
- Revenue growth (YoY)
- 63.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 15.1%
- Net margin
- −3.5%
Higher than 88% of US stocks
Higher than 73% of US stocks
Higher than 25% of US stocks
- Return on equity
- −28.7%
- Return on assets
- −2.7%
- Dividend yield
- 0.0%
Higher than 28% of US stocks
Higher than 36% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Basel Medical Group Ltd. (BMGL) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Basel Medical Group Ltd. has a market value of $70.8M and an enterprise value of $13.1M.
Trailing P/E: 115.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Basel Medical Group Ltd. employs 82 people.
Data provided by Twelve Data
BMGL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Basel Medical Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BMGL stock
How does Ticker Nerd's model rank BMGL?
As at 4 Nov 2026, Basel Medical Group Ltd. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).
What is the BMGL stock forecast for 2030?
No analyst covering Basel Medical Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMGL are extrapolating price history, which says nothing about the business.
What does Basel Medical Group Ltd. do?
Basel Medical Group Ltd is a Singapore-based healthcare services provider focused on specialist medical care across orthopedics, trauma, sports medicine, neurosurgery, and general practice. The company delivers consultations, medical diagnosis, and both surgical and non-surgical treatments, with services that include joint replacement, spine care, foot and ankle procedures, minimally invasive orthopedic care, physiotherapy, and rehabilitation.
About Basel Medical Group Ltd.
Basel Medical Group Ltd is a Singapore-based healthcare services provider focused on specialist medical care across orthopedics, trauma, sports medicine, neurosurgery, and general practice. The company delivers consultations, medical diagnosis, and both surgical and non-surgical treatments, with services that include joint replacement, spine care, foot and ankle procedures, minimally invasive orthopedic care, physiotherapy, and rehabilitation. It also offers health screening, mental health, and women’s health services, supporting a broader patient-care pathway within its clinics and medical centers. Basel Medical Group Ltd operates within the healthcare services market, where it serves patients seeking integrated treatment across multiple disciplines and procedures. Its current business model centers on clinical care delivery and specialist expertise in private healthcare settings in Singapore.
CEO Dr. Yen Feng Chhoa M.D. · 82 employees · Singapore · https://baselmedical.com